James Frates, Vice President and Chief Financial Officer of Alkermes, Inc., will present an overview of the company at 2:30pm ET on Thursday, August 2, 2001, from the Boston Marriott Long Wharf, Boston, MA.
Alkermes is a leader in the development of products based on sophisticated drug delivery technologies. Its first product, Nutropin Depot(TM), is a long-acting form of Genentech's recombinant human growth hormone using Alkermes' ProLease(R) technology. The company has several areas of focus, including (i) controlled, sustained release of injectable drugs lasting several days to several weeks, utilizing its ProLease and Medisorb(R) technologies and (ii) the development of pharmaceutical products based on proprietary pulmonary drug delivery technologies utilizing its AIR(TM) technology. In addition to its Cambridge, Massachusetts headquarters, research and manufacturing facilities, Alkermes operates research and manufacturing facilities in Ohio and a medical affairs office in Cambridge, England.
CONTACT: Alkermes, Inc.
Rebecca Peterson
(617) 583-6378